NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRI)

1.5900 -0.1200 (-7.02%)
At close: April 26 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Hermann Luebbert Ph.D. CEO, President & Executive Chairman 733.23k -- 1956
Mr. Eugene Frederick Leffler III Chief Financial Officer 378.58k -- 1985
Ms. Erica F. Gates CPA, M.B.A. Senior Director of Finance & Principal Accounting Officer -- -- --
Mr. Jon Lyons M.B.A., Ph.D. Vice President of Scientific & Medical Affairs -- -- --
Ms. Alycia Torres Vice President of Administration -- -- --
Mr. Daniel Hakansson J.D. General Counsel & Head of Compliance -- -- --
Ms. Samantha Widdicombe Senior Director of Strategic Accounts & Communications -- -- --
Mr. Mark Baldyga Vice President of Sales & Marketing -- -- --

Biofrontera Inc.

120 Presidential Way
Suite 330
Woburn, MA 01801
United States
781-245-1325 https://www.biofrontera-us.com
Sector: 
Healthcare
Full Time Employees: 
83

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 12, 2024 - May 27, 2024
Biofrontera Inc. Earnings Call

Related Tickers

PTPI Petros Pharmaceuticals, Inc.
0.6399
0.00%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3850
-0.90%
 
SNOA Sonoma Pharmaceuticals, Inc.
0.1590
-1.18%
 
SXTC China SXT Pharmaceuticals, Inc.
1.0500
+1.94%
 
RDHL RedHill Biopharma Ltd.
0.4280
+2.22%
 
SBFM Sunshine Biopharma, Inc.
0.9500
+17.66%
 
LSDI Lucy Scientific Discovery Inc.
0.7597
-12.58%
 
MEDXF Medexus Pharmaceuticals Inc.
1.3850
+2.59%
 
AGRX Agile Therapeutics, Inc.
0.4000
0.00%
 
DERM Journey Medical Corporation
3.4000
-2.86%